PD
Showing 1 - 25 of >10,000
Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Lung Cancer
- Centipeda minima+PD-1/PD-L1 inhibitor
- PD-1/PD-L1 inhibitor
- (no location specified)
Feb 17, 2023
Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)
Recruiting
- Digestive System Cancers
- KN046
- +2 more
-
Beijing, ChinaPeking University Cancer Hospital
Oct 25, 2023
Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)
Completed
- Advanced Solid Tumor
- Inosine 0.2g orally 3 times/day
- PD-1/PD-L1 inhibitor ,chemotherapy/targeting
-
Beijing, Beijing, ChinaQin li
Mar 30, 2023
Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)
Not yet recruiting
- Advanced Non Small Cell Lung Cancer
- (no location specified)
Oct 24, 2023
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small
Recruiting
- Lung Cancer
-
Yiwu, Zhejiang, ChinaThe Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022
Parkinson's Disease (PD), Movement Disorders, Depression Trial in Changhua (probiotics, Placebo)
Not yet recruiting
- Parkinson's Disease (PD)
- +3 more
- probiotics
- Placebo
-
Changhua, TaiwanChanghua Christian Hospital (CCH)
Nov 6, 2023
Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)
Recruiting
- Hepatocellular Carcinoma
-
Shanghai, ChinaZhongshan Hospital Fudan university
Jan 31, 2023
Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)
Recruiting
- Biliary Tract Cancer
- +2 more
-
Shanghai, ChinaZhongshan hospital, Fudan University
Aug 12, 2023
Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)
Recruiting
- Hepatocellular Carcinoma
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
- TACE
-
Nanjing, China
- +1 more
Dec 28, 2022
Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,
Recruiting
- Advanced Lung Carcinoma
- LK101 injection (personlized neoantigen pulsed DC vaccine )
- +2 more
-
Beijing, Beijing, ChinaCancer hospital Chinese Academy of Medical Sciences
May 23, 2023
Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)
Recruiting
- Colorectal Liver Metastases
- Radiation: High- and Low-dose radiotherapy
- PD-1 Inhibitors
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Sep 13, 2023
High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1
Suspended
- NSCLC Stage IV
- NSCLC, Stage IIIC
- Primary Immune Response (PIR) test by Biodesix, Inc.
-
San Carlos, California
- +1 more
Jan 26, 2023
Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)
Not yet recruiting
- Esophageal Squamous Carcinoma
- HER-2 Protein Overexpression
- (no location specified)
Sep 24, 2023
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal
Completed
- Colorectal Cancer
- Fruquintinib combined with anti-PD-1 antibodies
-
ChangSha, Hunan, ChinaHunan Cancer Hospital
Aug 27, 2023
Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)
Recruiting
- Hepatocellular Carcinoma
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
- TACE
-
Nanjing, China
- +1 more
Dec 28, 2022
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
Peritoneal Dialysis Complication, Residual Kidney Function, Survival Trial (Single daily icodextrin exchange, Conventional PD
Not yet recruiting
- Peritoneal Dialysis Complication
- +3 more
- Single daily icodextrin exchange
- Conventional PD group
- (no location specified)
Nov 5, 2023
Chronic Kidney Diseases Trial in Singapore (AWAK PD)
Recruiting
- Chronic Kidney Diseases
- AWAK PD
-
Singapore, SingaporeSingapore General Hospital
Apr 12, 2023
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1
Active, not recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Jul 4, 2023
Bevacizumab Combined With PD-1 Monoclonal Antibody in
Not yet recruiting
- Colorectal Cancer
- Bevacizumab Combined With PD-1 Monoclonal Antibody
- (no location specified)
Nov 8, 2023
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Thymalfasin
- +3 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)
Not yet recruiting
- Rectal Cancer
- Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
- (no location specified)
Aug 29, 2023